NEUROLOGIE PRO PRAXI / Neurol. praxi. 2024;25(5):362-366 / www.neurologiepropraxi.cz 366 PŘEHLEDOVÉ ČLÁNKY Inhibítory komplementu ekulizumab a ravulizumab v liečbe generalizovanej myasténie gravis (gMG) ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. 5. European Medicines Agency. Ultomiris® (ravulizumab) Summary of Product Characteristics. Dostupné na: https://www. ema.europa.eu/sk/documents/product-information/ultomiris-epar-product-information_sk.pdf. 6. Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-Bacchi V. The Rational Use of Complement Inhibitors in Kidney Diseases. Kidney Int Rep. 2022;7(6):1165-1178. doi: 10.1016/j. ekir.2022.02.021. 7. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-43. doi: 10.1056/NEJMoa061648. 8. Howard Jr JF. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113128. doi: 10.1111/nyas.13522. 9. Howard Jr JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, doubleblind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1 10. Mantegazza R, O'Brien FL, Yountz M, Howard Jr JF, REGAIN Study Group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020;7(8):1327-1339. doi: 10.1002/acn3.51121 11. Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology. 2021;96(4):e610-e618. doi: 10.1212/ WNL.0000000000011207. 12. Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023 Aug;270(8):3862-3875. doi: 10.1007/ s00415-023-11699-x 13. Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020;11:538. doi: 10.3389/fneur.2020.00538. 14. Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14-24. doi: 10.1002/mus.26447. 15. Narayanaswami P, Sanders DB, Wolfe GI, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122. doi: 10.1212/ WNL.0000000000011124. 16. Pittock SJ, Berthele A, Fujihara K. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(7):614-625. doi: 10.1056/NEJMoa1900866. 17. Špalek P. Myasténia gravis. Cesk Slov Neurol N. 2008;71/104(1):7-24. 18. Špalek P. Intravenózny imunoglobulín v liečbe myasténie gravis. Neurológia. 2018;13:53-58. 19. Vanoli F, Mantegazza R. Current drug treatment of myasthenia gravis. Curr Opin Neurol. 2023;36(5):410-415. doi: 10.1097/WCO.0000000000001196. 20. Voháňka S. Farmakoterapie myasthenia gravis. Neurol. praxi. 2010;11(2):95-99. 21. Vissing J, Jacob S, Fujita KP, et al., REGAIN Study Group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurology. 2020;267(7):19912001. doi: 10.1007/s00415-020-09770-y. 22. Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. Neurol Ther. 2023;12(5):1435-1438. doi: 0.1007/s40120-023-00514-4. 23. Vu T, Ortiz S, Katsuno M, et al. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol. 2023;270(6):3129-3137. doi: 10.1007/s00415-023-11617-1. 24. Vu T, Wiendl H, Katsuno M, et al. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence. Neuropsychiatr Dis Treat. 2023;19:2639-2655. doi: 10.2147/NDT.S374694. 25. Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34(11):22612277. doi: 10.1007/s00467-018-4091-3. 26. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016;375(6):511-22. doi: 10.1056/NEJMoa1602489. ODBORNÝ GARANT: doc. MUDr. Irena Doležalová, Ph.D. POŘADATEL: Společnost SOLEN, s. r. o., ve spolupráci s I. neurologickou klinikou LF MU a FN u sv. Anny ZLATÝ PARTNER Registrace ZDARMA TERMÍN květen 2024 až duben 2025 ON LINE KURZ OBSAH KURZU Co víme o syndromu Dravetové u dospělých? – prof. MUDr. Petr Marusič, Ph.D. Na co ještě myslet u dětí? – MUDr. Martin Kudr, Ph.D. Cesta k diagnóze – dialog s genetikem – MUDr. Katalin Štěrbová Cesta k diagnóze – dialog s genetikem – MUDr. Jana Zárubová Cesta k diagnóze – dialog s genetikem – MUDr. Markéta Vlčková, Ph.D. Mechanismus účinku a protizáchvatová aktivita fen uraminu – MUDr. Ondřej Horák, doc. MUDr. Irena Doležalová, Ph.D. Zaostřeno na syndrom Dravetové dostupný na online.solen.cz
RkJQdWJsaXNoZXIy NDA4Mjc=